AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC) is a phase 2, randomised interventional study registered as NCT07544784 by Fudan University, with a registry enrolment figure of 73 participants, started 2025-11-04 and due to reach its primary completion in 2027-12-01. Interventions recorded: AK104 with radiotherapy; Standard of therapy. Conditions listed: Colorectal Cancer Liver Metastases (CRLM). Primary outcome: ORR. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed colorectal cancer;". Sites: China. No results are recorded here; the registry entry is the source.